Bioproduction

For a leading vaccine player, Alcimed conducted a comparative analysis to understand vaccine manufacturing steps across key stakeholders in the vaccine industry. The project aimed to understand the commercial application of the products as well as the current market offer.

Our team performed a comparative benchmarking across available bioprocessing services, evaluating their status-quo with respect to elements such as scalability and cost, while also considering regulatory aspects.

The project considered the role of external factors, such as differences in manufacturing facilities or geographical specificities for each analysed site. At the end, our team was able to propose key next steps for a unique value proposition and differentiation from competitors.

Our team helped a player in the bioprocessing field to improve the production of alternative proteins.

The project consisted in understanding current methods (for instance, in yeasts and bacteria), while assessing their optimisation potential in the near and mid-terms.

Recommendations were built upon the identification of the main biotechnologies and potential partners, based on roadblocks and main opportunities.

Alcimed supported an emerging biotechnology company in the search for partners to set up a novel bioprocessing technology aiming to produce more affordable, and consequentially more accessible, pharmaceutical products (biosimilars) in developing countries.

To do so, our team helped in identifying funding resources, organizations and potential partners to set up the technology and the production platform of our client in the designated low- and middle-income countries.

In this project, we exchanged with Key Opinion Leaders (KOLs) promoting local pharmaceutical production and access to medicines in the countries in-scope, as well as started discussions with international organizations providing resources for the establishment of healthcare production facilities in low-income countries including NGOs, investment funds & governmental organizations.

Alcimed supported a European bioprocessing player in the definition of its CDMO strategy for biomanufacturing innovative therapies for third parties.

This project explored how our client’s current solutions are perceived, and benchmarked international solutions to identify best practices. The strategic analysis also included an assessment of several scenarios and an understanding of the different implications regarding financial, legal and organizational aspects. Our team then defined a roadmap to implement the preferred scenario, accompanied by a customizable business plan (financial, HR).

Following market validation of our client’s value proposition, our project team proposed a new operational model for our client’s biomanufacturing activity, aiming at better adapting the offer to the challenges of the market and the dynamics of the local ecosystem.

Our client, a leading pharmaceutical company, sought to develop new technological platforms for bioprocessing beyond oncolytic viruses. Their focus was to assess the potential of exosome technologies and integrate them into their strategic roadmap.

To achieve this, we conducted a comprehensive exploration of exosome technologies, examining market trends, regulatory landscapes, and key players. We engaged with industry pioneers and gathered cutting-edge insights from KOLs in the field of exosomes and extracellular vesicles. Based on our findings, we recommended strategic positioning for leveraging exosome technologies in bioprocessing innovation.

The impact for the client was significant. The synthesis of key aspects of exosome technology was presented to their scientific advisory board, providing the strategic guidance needed to make informed decisions. This positioned them at the forefront of bioprocessing innovation.

Alcimed conducted a global search for companies, technologies, patents, and research groups who have advanced the ability to incorporate non-canonical amino acids into expressed recombinant proteins for a global pharmaceutical player.

We used a combination of interviews, literature research, and database mining to create an overview of companies with the ability to express recombinant proteins that contain non-canonical amino acids.

This research aided our client by revealing early stage technologies that are ripe for investment, identifying potential partners for the bioproduction of proteins with non-canonical amino acids, and by discovering new companies in this space previously unknown to our client.

White biotechnology uses microorganisms, often engineered via synthetic biology, to industrially produce chemicals and materials. We accompanied an industrial launching an innovation hub on sustainable materials understand the number and economic sectors of white biotechnology start-ups in Europe.

We also investigated the demand for white biotechnology products as well as trends in the technological applications for white biotechnology in Europe.

Through our results, we helped our client understand that the bioproduction infrastructure necessary for companies to develop white biotechnology, even at the pilot and demonstration stage, is still insufficient in Europe, and what his hub could provide to fill some of the gaps.

Our client, one of the largest French urban areas, wanted to understand the areas to prioritize in its health sector in order to implement a strategy that would offer support and attract industrial projects.

After an internal sector inventory and understanding the overall dynamics and policies of the field’s investments, we identified e-health and bioproduction as two particularly pertinent sectors.
In the context of our project, the client could deploy a roadmap and plan of actions to implement in the healthcare domain.

This included a targeted policy to attract a pharmaceutical production unit by making direct contact with players in the healthcare sector, and presenting the region’s value proposition to attract future investment.